PFIZER INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
A Study to Determine the Effects of PF-04965842 on the Pharmacokinetics of Oral Contraceptive Steroids in Healthy Female Subjects
- Conditions
- Healthy Females
- Interventions
- First Posted Date
- 2018-09-07
- Last Posted Date
- 2020-03-23
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 17
- Registration Number
- NCT03662516
- Locations
- 🇺🇸
Pfizer New Haven Clinical Research Unit, New Haven, Connecticut, United States
A Renal Impairment Study for PF-04965842
- First Posted Date
- 2018-09-06
- Last Posted Date
- 2022-03-22
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 23
- Registration Number
- NCT03660241
- Locations
- 🇺🇸
University of Miami, Sylvester Comprehensive Cancer Center, Miami, Florida, United States
🇺🇸Orlando Clinical Research Center, Orlando, Florida, United States
🇺🇸University of Miami Division of Clinical Pharmacology, Miami, Florida, United States
A Study to Evaluate the PF-06700841 Effect on QTc Interval in Healthy Volunteers
- First Posted Date
- 2018-09-04
- Last Posted Date
- 2019-02-27
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 33
- Registration Number
- NCT03656952
- Locations
- 🇧🇪
Pfizer Clinical Research Unit, Brussels, Belgium
A Safety Study For Prevenar 13 Among Chinese Children
- Conditions
- SeizuresApneaFeverUrticaria and Angioedema
- First Posted Date
- 2018-09-04
- Last Posted Date
- 2021-08-27
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 21240
- Registration Number
- NCT03656939
- Locations
- 🇨🇳
School of Public Health at Fudan University, Shanghai, China
A Study to Determine the Effects of PF-04965842 on Midazolam PK in Healthy Volunteers
- First Posted Date
- 2018-08-27
- Last Posted Date
- 2020-03-23
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 25
- Registration Number
- NCT03647670
- Locations
- 🇧🇪
Pfizer Clinical Research Unit, Brussels, Belgium
Xeljanz Special Investigation for Long-term Use in UC Patients
- Conditions
- Ulcerative Colitis
- First Posted Date
- 2018-08-22
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 2016
- Registration Number
- NCT03643211
- Locations
- 🇯🇵
Pfizer Local Country Office, Tokyo, Japan
Avelumab and Talazoparib in Untreated Advanced Ovarian Cancer (JAVELIN OVARIAN PARP 100)
- Conditions
- Ovarian Cancer
- Interventions
- Drug: Chemotherapy + avelumab followed by avelumab + talazoparibDrug: Chemotherapy followed by talazoparib maintenanceDrug: Chemotherapy + bevacizumab followed by bevacizumab
- First Posted Date
- 2018-08-22
- Last Posted Date
- 2023-04-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 79
- Registration Number
- NCT03642132
- Locations
- 🇰🇷
Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of
🇷🇺Limited Liability Company "VitaMed" (LLC "VitaMed"), Moscow, Russian Federation
🇮🇪Bon Secours Hospital, Cork, Ireland
Trial to Evaluate the Safety and Immunogenicity of Multivalent Pneumococcal Vaccines in Japanese Adults 18 to 49 Years of Age
- Conditions
- Pneumococcal Infections
- Interventions
- Biological: multivalent pneumococcal conjugate formulation 1Biological: Prevnar 13Biological: multivalent pneumococcal conjugate formulation 2
- First Posted Date
- 2018-08-22
- Last Posted Date
- 2019-06-12
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 104
- Registration Number
- NCT03642847
- Locations
- 🇺🇸
East-West Medical Research Institute, Honolulu, Hawaii, United States
🇺🇸Collaborative Neuroscience Network, LLC., Long Beach, California, United States
🇺🇸Clinilabs Drug Development Corporation, Eatontown, New Jersey, United States
A Study of Avelumab, Binimetinib and Talazoparib in Patients With Locally Advanced or Metastatic RAS-mutant Solid Tumors
- Conditions
- Pancreatic Cancer
- Interventions
- First Posted Date
- 2018-08-20
- Last Posted Date
- 2022-01-26
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 36
- Registration Number
- NCT03637491
- Locations
- 🇺🇸
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸University of Utah, Huntsman Cancer Hospital, Salt Lake City, Utah, United States
🇺🇸University of Utah, Huntsman Cancer Institute, Salt Lake City, Utah, United States
Drug Interaction Study Evaluating the Effect of Rifampin on PK and Safety of PF 04965842.
- First Posted Date
- 2018-08-20
- Last Posted Date
- 2020-02-28
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT03637790
- Locations
- 🇧🇪
Pfizer Clinical Research Unit, Brussels, Belgium